Hyperleptinemia as a Component of a Metabolic Syndrome of Cardiovascular Risk

<jats:p> <jats:italic>Abstract</jats:italic> —In humans, production of the adipocyte-derived peptide leptin has been linked to adiposity, insulin, and insulin sensitivity. We therefore considered that alterations in plasma leptin concentrations could constitute an additional component of a metabolic syndrome of cardiovascular risk. To explore this hypothesis, we employed factor analysis, a multivariate statistical technique that allows reduction of large numbers of highly intercorrelated variables to composite, biologically meaningful factors. Seventy-four men [age, 48.4±1.3 years (mean±SEM); body mass index (BMI), 25.6±0.3 kg/m <jats:sup>2</jats:sup> ] who were free of coronary heart disease and diabetes underwent anthropometric measurements (subscapular-to-triceps [S:T] and subscapular-to-biceps [S:B] skinfold thickness ratios, measurement of fasting plasma leptin, and an intravenous glucose tolerance test (IVGTT) for assessment of insulin sensitivity. Plasma leptin concentrations were correlated with BMI ( <jats:italic>r</jats:italic> =0.57, <jats:italic>P</jats:italic> <0.001), S:T ( <jats:italic>r</jats:italic> =0.34, <jats:italic>P</jats:italic> =0.003), S:B ( <jats:italic>r</jats:italic> =0.37, <jats:italic>P</jats:italic> <0.001), systolic and diastolic blood pressures (both <jats:italic>r</jats:italic> =0.24, <jats:italic>P</jats:italic> =0.044), fasting triglycerides ( <jats:italic>r</jats:italic> =0.31, <jats:italic>P</jats:italic> =0.007), serum uric acid ( <jats:italic>r</jats:italic> =0.35, <jats:italic>P</jats:italic> =0.003), fasting glucose ( <jats:italic>r</jats:italic> =0.32, <jats:italic>P</jats:italic> =0.003) and insulin ( <jats:italic>r</jats:italic> =0.33, <jats:italic>P</jats:italic> =0.004), and IVGTT insulin ( <jats:italic>r</jats:italic> =0.63, <jats:italic>P</jats:italic> <0.001). A negative correlation was observed between leptin and insulin sensitivity ( <jats:italic>r</jats:italic> =−0.32, <jats:italic>P</jats:italic> =0.006). No significant correlations emerged between plasma leptin concentrations and age, high density lipoprotein cholesterol, or IVGTT glucose. In multivariate regression analyses, BMI (standardized coefficient [SC] =0.40, <jats:italic>P</jats:italic> =0.001), fasting insulin (SC=0.23, <jats:italic>P</jats:italic> =0.036), and IVGTT insulin (SC=0.51, <jats:italic>P</jats:italic> <0.001) emerged as independent predictors of plasma leptin concentrations ( <jats:italic>R</jats:italic> <jats:sup>2</jats:sup> =0.56, <jats:italic>P</jats:italic> <0.001). After adjustment for BMI, only IVGTT insulin emerged as a significant predictor of plasma leptin concentrations (SC=0.56, <jats:italic>P</jats:italic> <0.001, <jats:italic>R</jats:italic> <jats:sup>2</jats:sup> =0.45, <jats:italic>P</jats:italic> <0.001). Factor analysis of plasma leptin concentrations and the variables that are considered relevant to the insulin resistance syndrome revealed a clustering of plasma leptin concentrations with a factor dominated by insulin resistance and high IVGTT insulin, separate from a high IVGTT glucose/central obesity factor and a high triglyceride/low high density lipoprotein cholesterol factor. Together, these factors accounted for 55.9% of the total variance in the dataset. In conclusion, interindividual variations in plasma leptin concentrations are strongly related to the principal components of the insulin resistance syndrome. Further studies are needed to determine whether the insulin-leptin axis plays a coordinating role in this syndrome and whether plasma leptin concentrations could provide an additional measure of cardiovascular risk. </jats:p>